IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On February 13, 2017, Imprimis Pharmaceuticals, Inc. (the
Company) entered into a Stock Purchase Agreement (the Agreement)
with Livernois London, LLC (Livernois). to the terms of the
Agreement, Imprimis sold to Livernois and Livernois purchased
from Imprimis one hundred percent (100%) of the issued and
outstanding shares of common stock of Imprimis Texas based
subsidiary, ImprimisRx TX, Inc dba ImprimisRx (Imprimis TX).
Imprimis ceased operations of Imprimis TX in 2016 and the
Agreement does not transfer to Livernois any Company rights to
intellectual property, products, clients, nor any existing
Company business operations. As consideration for the purchase of
Imprimis TX, Livernois paid the Company $10,000 and the Company
assigned, and Livernois assumed, the remaining lease obligation
totaling $112,578 for its Texas based facility.
The foregoing is only a brief description of the Agreement and
does not purport to be a complete description of the rights and
obligations of the parties thereunder and is qualified in its
entirety by reference to the full text of the document, which is
filed as Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 2.01 Completion of Acquisition or Disposition of
Assets.
The information set forth in Item 1.01 of this Current Report on
Form 8-K is incorporated by reference into this Item 2.01 in its
entirety.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 10.1 |
Stock Purchase Agreement dated February 13, 2017 between Imprimis Pharmaceuticals, Inc. and Livernois London, LLC |
About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas. IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Recent Trading Information
IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) closed its last trading session down -0.25 at 2.54 with 142,581 shares trading hands.
